Jump to content

Joe M. McCord

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by StefenTower (talk | contribs) at 08:16, 12 November 2023 (→Pathways Bio: Typo fixing + cleanups, typo(s) fixed: ’s → 's). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Joe Milton McCord
BornMarch 3, 1945 (1945-03-03) (age 79)
CitizenshipUnited States
Alma materRhodes College, Duke University
Known forDiscovery of superoxide dismutase
Scientific career
FieldsBiochemistry
InstitutionsUniversity of Colorado
Doctoral advisorIrwin Fridovich

Joe Milton McCord (born March 3, 1945) is an American biochemist. While serving as a graduate student, he and his supervisor Irwin Fridovich were the first to describe the enzymatic activity of superoxide dismutase.[1][2] McCord joined the board of directors of the LifeVantage Corporation (makers of the dietary supplement Protandim) in 2006, serving as the company's chief science officer from 2011 to 2012, and retired from the company in June 2013.[3]

Academic background

McCord received a B.S. degree in chemistry from Rhodes College (graduated 1966) and a Ph.D. in biochemistry from Duke University (graduated 1970), where he also conducted postdoctoral research.[citation needed]

McCord is a past recipient of the Discovery Award from the Society for Free Radical Biology and Medicine (shared with Irwin Fridovich),[4] the Elliott Cresson Medal, and a Lifetime Achievement Award from the Oxygen Society.[citation needed]

LifeVantage/Protandim

McCord served on the board of directors (Director of Science) of the LifeVantage Corporation beginning in 2006 and was listed by the SEC as an insider shareholder.[5] LifeVantage is a Utah-based multilevel marketing company that distributes an antioxidant dietary supplement known as Protandim. McCord co-authored 7 studies on the product[6][7][8][9][10][11][12] and participated in distributor training.[5] McCord served as chief scientific officer for LifeVantage from June 2011 until September 2012, and then became a member of the company's science advisory board. LifeVantage announced McCord's retirement in June 2013.[3][13] Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company.[13]

Pathways Bio

McCord co-founded Pathways Bioscience to improve health span and overcome health and wellness problems associated with aging by supporting the body's own defense mechanisms that allow it to protect and heal itself. Pathways Bioscience is focused on the discovery and development of new agents that regulate gene expression and exert beneficial effects by influencing cell defense pathways.[14]

References

  1. ^ McCord JM, Fridovich I (November 1969). "Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein)". J. Biol. Chem. 244 (22): 6049–55. doi:10.1016/S0021-9258(18)63504-5. PMID 5389100.
  2. ^ Keele BB, McCord JM, Fridovich I (November 1970). "Superoxide dismutase from escherichia coli B. A new manganese-containing enzyme". J. Biol. Chem. 245 (22): 6176–81. doi:10.1016/S0021-9258(18)62675-4. PMID 4921969.
  3. ^ a b Corporation, Lifevantage (25 June 2013). "Dr. Joe McCord, LifeVantage Corporation's First Chief Science Officer, Retires From Company". GlobeNewswire News Room. Retrieved 19 April 2021.
  4. ^ "SFRBM - Society for Free Radical Biology and Medicine".
  5. ^ a b http://secwatch.com/mccord-joe-m[full citation needed]
  6. ^ Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM (January 2006). "The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy". Free Radic. Biol. Med. 40 (2): 341–7. doi:10.1016/j.freeradbiomed.2005.08.043. PMID 16413416.
  7. ^ Velmurugan K, Alam J, McCord JM, Pugazhenthi S (February 2009). "Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim". Free Radic. Biol. Med. 46 (3): 430–40. doi:10.1016/j.freeradbiomed.2008.10.050. PMID 19056485.
  8. ^ Liu J, Gu X, Robbins D, et al. (2009). "Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model". PLOS ONE. 4 (4): e5284. Bibcode:2009PLoSO...4.5284L. doi:10.1371/journal.pone.0005284. PMC 2668769. PMID 19384424.
  9. ^ Robbins D, Gu X, Shi R, et al. (2010). "The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesis". PLOS ONE. 5 (7): e11902. Bibcode:2010PLoSO...511902R. doi:10.1371/journal.pone.0011902. PMC 2912769. PMID 20689586.
  10. ^ Bogaard HJ, Natarajan R, Henderson SC, et al. (November 2009). "Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure". Circulation. 120 (20): 1951–60. doi:10.1161/CIRCULATIONAHA.109.883843. PMID 19884466.
  11. ^ Qureshi MM, McClure WC, Arevalo NL, et al. (June 2010). "The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice". J Diet Suppl. 7 (2): 159–178. doi:10.3109/19390211.2010.482041. PMC 2926985. PMID 20740052.
  12. ^ Joddar B, Reen RK, Firstenberg MS, et al. (March 2011). "Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway". Free Radic. Biol. Med. 50 (6): 700–9. doi:10.1016/j.freeradbiomed.2010.12.008. PMID 21167278.
  13. ^ a b "Form 8-K for LifeVantage Corp". Yahoo.com. June 25, 2013. Retrieved November 10, 2013.
  14. ^ https://www.pathwaysbio.com/
Retrieved from "https://en.wikipedia.org/w/index.php?title=Joe_M._McCord&oldid=1184734646"